Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
BMC Health Serv Res ; 18(1): 764, 2018 Oct 10.
Article in English | MEDLINE | ID: mdl-30305057

ABSTRACT

BACKGROUND: Differences in cancer survival exist between countries in Europe. Benchmarking of good practices can assist cancer centers to improve their services aiming for reduced inequalities. The aim of the BENCH-CAN project was to develop a cancer care benchmark tool, identify performance differences and yield good practice examples, contributing to improving the quality of interdisciplinary care. This paper describes the development of this benchmark tool and its validation in cancer centers throughout Europe. METHODS: A benchmark tool was developed and executed according to a 13 step benchmarking process. Indicator selection was based on literature, existing accreditation systems, and expert opinions. A final format was tested in eight cancer centers. Center visits by a team of minimally 3 persons, including a patient representative, were performed to verify information, grasp context and check on additional questions (through semi-structured interviews). Based on the visits, the benchmark methodology identified opportunities for improvement. RESULTS: The final tool existed of 61 qualitative and 141 quantitative indicators, which were structured in an evaluative framework. Data from all eight participating centers showed inter-organization variability on many indicators, such as bed utilization and provision of survivorship care. Subsequently, improvement suggestions for centers were made; 85% of which were agreed upon. CONCLUSION: A benchmarking tool for cancer centers was successfully developed and tested and is available in an open format. The tool allows comparison of inter-organizational performance. Improvement opportunities were successfully identified for every center involved and the tool was positively evaluated.


Subject(s)
Benchmarking , Cancer Care Facilities/standards , Accreditation , Europe , Pilot Projects , Reproducibility of Results
2.
PLoS One ; 18(11): e0293965, 2023.
Article in English | MEDLINE | ID: mdl-37948427

ABSTRACT

OBJECTIVES: 1) to analyse the total average healthcare costs of a patient with an out-of-hospital cardiac arrest (OHCA), as well as estimating the operational costs of the citizen-rescuer system (CRS); 2) to conduct an early modelling of the effects and healthcare costs of the Dutch CRS in comparison to no CRS. METHODS: A health economic modelling study was conducted. Adult patients with OHCA from cardiac causes in the province of Limburg (the Netherlands) were included. The time horizon was from OHCA occurrence up to one year after hospital discharge. First, the total average healthcare costs of OHCA patients were analysed as well as the yearly operating costs of the CRS. Second, an early modelling was conducted to compare from the healthcare perspective the healthcare costs of OHCA patients with the CRS being activated but no responders attended (CRS-NV) versus the CRS being activated with attendance of ≥1 responder(s) (CRS-V). RESULTS: The total average healthcare costs per patient are €42,533. The yearly operating costs for the CRS are approximately €1.5 million per year in the Netherlands. The early modelling of costs and effects showed that the incremental healthcare costs per patient thus were €4,131 in the CRS-V versus the CRS-NV group (€25,184 in the CRS-V group and €21,053 in the CRS-NV group). Incremental quality-adjusted life years (QALYs) was 5 per 100 patients (16 per 100 patients in the CRS-V group versus 11 per 100 patients in the CRS-NV group). The incremental cost-effectiveness ratio (ICER) was €79,662 per QALY for the CRS-V group. CONCLUSION: This study shows that patients in the CSR-V group had additional health care costs of €4,131 per patient compared to patients in the CRS-NV group. This increase is caused by patients surviving more often, who then continue to utilise health services, which results in a (logic) increase in healthcare costs. For future research, accurate and up-to-date data on effectiveness and costs of the CRS needs to be collected.


Subject(s)
Out-of-Hospital Cardiac Arrest , Adult , Humans , Out-of-Hospital Cardiac Arrest/epidemiology , Out-of-Hospital Cardiac Arrest/therapy , Health Care Costs , Netherlands/epidemiology , Cost-Benefit Analysis , Quality-Adjusted Life Years
3.
OMICS ; 22(9): 616-625, 2018 09.
Article in English | MEDLINE | ID: mdl-30235108

ABSTRACT

Antibiotics (AB) can reduce morbidity and mortality in the treatment of patients with sepsis and chronic obstructive pulmonary disease (COPD) exacerbations. Yet, AB overuse or misuse increases antibiotic resistance (ABR) and Clostridium difficile infections (CDI). This study projected the expected impact of a procalcitonin (PCT) biomarker testing strategy on incremental ABR cases and CDI, and costs of care in a population of patients hospitalized with suspected sepsis or a COPD exacerbation, in three European countries: the United Kingdom, Germany, and the Netherlands. Based on a systematic literature search and a decision model, we analyzed the number of ABR and CDI cases avoided and the incremental healthcare costs per patient from a societal perspective over the time horizon of a hospital stay. In the sepsis population, the PCT-guided antibiotic prescription strategy was projected to reduce the number of ABR cases with circa 6%, the number of CDI cases with 21%, and societal costs with circa €1300 per patient. In the COPD population, the number of ABR and CDI cases is reduced with circa 50%, and societal cost savings ranged €1701, €2473, and €2435 per patient in Germany, the Netherlands, and the United Kingdom, respectively. Model outcomes were most sensitive to the impact of the PCT-guided strategy on the number of intensive care unit days and general hospital ward days. Taken together, a PCT biomarker-guided antibiotic management strategy is likely to reduce the number of ABR and CDI cases and generate cost savings in a population of patients hospitalized with suspected sepsis or with a COPD exacerbation.


Subject(s)
Clostridium Infections/metabolism , Procalcitonin/metabolism , Anti-Bacterial Agents/therapeutic use , Biomarkers/analysis , Biomarkers/metabolism , Germany , Humans , Netherlands , United Kingdom
4.
J Clin Virol ; 39(1): 27-33, 2007 May.
Article in English | MEDLINE | ID: mdl-17409017

ABSTRACT

BACKGROUND: Highly pathogenic avian influenza (HPAI) H5N1 has spread globally in birds and infected over 270 humans with an apparently high mortality rate. Serologic studies to determine the extent of asymptomatic H5N1 infection in humans and other mammals and to investigate the immunogenicity of current H5N1 vaccine candidates have been hampered by the biosafety requirements needed for H5N1 micro-neutralization tests. OBJECTIVE: Development of a serodiagnostic tool for highly pathogenic influenza that reproduces H5N1 biology but can be used with less biohazard. STUDY DESIGN: We have generated and evaluated H5 hemagglutinin pseudotyped lentiviral particles encoding the luciferase reporter (H5pp). RESULTS: H5pp entry into target cells depends on alpha2-3 cell surface sialic acids and requires low pH for membrane fusion. H5pp infectivity is specifically neutralized by sera from patients and animals infected with H5N1 and correlates well with conventional microneutralization test. CONCLUSIONS: H5pp reproduce H5N1 influenza virus entry into target cells and potentially provides a high-throughput and safe method for sero-epidemiology.


Subject(s)
Hemagglutinin Glycoproteins, Influenza Virus/metabolism , Influenza A Virus, H5N1 Subtype/physiology , Influenza in Birds/diagnosis , Influenza in Birds/virology , Influenza, Human/diagnosis , Influenza, Human/virology , Lentivirus/physiology , Virion/physiology , Animals , Birds , Dogs , Hemagglutinin Glycoproteins, Influenza Virus/biosynthesis , Hemagglutinin Glycoproteins, Influenza Virus/genetics , Humans , Influenza A Virus, H5N1 Subtype/genetics , Influenza A Virus, H5N1 Subtype/pathogenicity , Influenza in Birds/blood , Influenza, Human/blood , Lentivirus/genetics , Lentivirus/pathogenicity , Luciferases/genetics , Neutralization Tests/methods , Serologic Tests/methods , Virion/genetics , Virion/pathogenicity
5.
FEBS Lett ; 554(3): 363-8, 2003 Nov 20.
Article in English | MEDLINE | ID: mdl-14623095

ABSTRACT

Until recently, it was assumed that polarity and axis formation have evolved only in metazoan phyla higher than Cnidaria. One key molecule involved in the signal transduction causing tissue polarity is Frizzled, a seven-transmembrane receptor that is activated by the Wnt family of secreted proteins. We report the isolation and characterization of a Frizzled gene from the demosponge Suberites domuncula (Sd-Fz). The deduced polypeptide comprises all characteristic domains known from Frizzled receptors of higher metazoans. In situ hybridization studies show that Sd-Fz is expressed in cells close to the surface of the sponges and in the pinacocytes of some canals. Northern blot analysis demonstrates its upregulation during the formation of three-dimensional sponge cell aggregates in culture. These data provide for the first time experimental evidence that already in the lowest metazoan phylum (Porifera) genes are present which are very likely involved in tissue polarity.


Subject(s)
Epithelium/metabolism , Porifera/metabolism , Receptors, Cell Surface/metabolism , Amino Acid Sequence , Animals , Blotting, Northern , Cell Aggregation/physiology , In Situ Hybridization , Molecular Sequence Data , Phylogeny , Porifera/cytology , Porifera/growth & development , Porifera/ultrastructure , Protein Structure, Tertiary , Receptors, Cell Surface/chemistry , Receptors, Cell Surface/genetics , Receptors, Cell Surface/isolation & purification , Sequence Homology, Amino Acid , Signal Transduction , Up-Regulation
7.
J Cell Sci ; 116(Pt 3): 513-24, 2003 Feb 01.
Article in English | MEDLINE | ID: mdl-12508112

ABSTRACT

Nuclear domains called ND10 or PML bodies might function as nuclear depots by recruiting or releasing certain proteins. Although recruitment of proteins through interferon-induced upregulation and SUMO-1 modification level of PML had been defined, it is not known whether release of proteins is regulated and has physiological consequences. Exposure to sublethal environmental stress revealed a sequential release of ND10-associated proteins. Upon heat shock Daxx and Sp100 were released but PML remained, whereas exposure to subtoxic concentrations of CdCl(2) induced the release of ND10-associated proteins, including PML, with Sp100 remaining in a few sites. In both cases, recovery times were similar and were followed by a burst of mitotic activity. Cadmium-induced release of proteins from ND10 could be blocked by inhibiting activation of p38 MAPK or ERK1/2. By contrast, heat-shock-induced desumolation of PML and release of proteins from ND10 are unaffected by these inhibitors but can be recapitulated by overexpression of the SUMO isopeptidase SENP-1. Therefore, activation of SENP-1-like SUMO isopeptidase(s) during heat shock is not affected by these kinases. Thus, the release of ND10-associated proteins is not due to a general dispersal of nuclear domains but seems to be regulated by rapid desumolation during thermal stress and through the phosphorylation cascade of stress and mitogenic signaling pathways in the case of CdCl(2). Whether the release of certain proteins had consequences was tested for heat-shock-protein transcription and synthesis. Release of Daxx correlated with Hsp25 suppression, suggesting that Daxx normally inhibits immediate Hsp25 production. Release of PML correlated with lower production of Hsp70. These results suggest that segregation or release of PML or Daxx have differential physiological relevance during the stress response. The fact that enzymatic activation of protein release or segregation after stress modifies the heat-shock response strengthens the concept of ND10 as a regulated depot of effector proteins.


Subject(s)
Carrier Proteins/biosynthesis , Cell Nucleus Structures/metabolism , Eukaryotic Cells/metabolism , Heat-Shock Proteins/biosynthesis , Heat-Shock Response/physiology , Intracellular Signaling Peptides and Proteins , Neoplasm Proteins/biosynthesis , Nuclear Proteins/biosynthesis , Transcription Factors/biosynthesis , Animals , Cadmium/pharmacology , Carrier Proteins/drug effects , Carrier Proteins/genetics , Cell Nucleus Structures/drug effects , Cell Nucleus Structures/genetics , Cells, Cultured , Co-Repressor Proteins , Cysteine Endopeptidases , Endopeptidases/genetics , Endopeptidases/metabolism , Enzyme Inhibitors/pharmacology , Eukaryotic Cells/drug effects , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , HSP70 Heat-Shock Proteins/biosynthesis , HSP70 Heat-Shock Proteins/genetics , Heat-Shock Proteins/genetics , Heat-Shock Response/drug effects , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Macromolecular Substances , Mice , Molecular Chaperones , Neoplasm Proteins/drug effects , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Nuclear Proteins/drug effects , Nuclear Proteins/genetics , Promyelocytic Leukemia Protein , SUMO-1 Protein/genetics , SUMO-1 Protein/metabolism , Stress, Physiological/genetics , Stress, Physiological/metabolism , Transcription Factors/drug effects , Transcription Factors/genetics , Tumor Suppressor Proteins
SELECTION OF CITATIONS
SEARCH DETAIL